VILIP-1 Expected to Be a Better Biomarker

VILIP-1 Expected to Be a Better Biomarker According to the new study carried out by researchers at the Washington University School of Medicine in St. Louis, patients diagnosed with very mild Alzheimer's disease (AD) are expected to experience a decline in their cognitive abilities after approximately three years.

This decline can be estimated by estimating the level of visininlike protein 1 (VILIP-1) in cerebrospinal fluid (CSF). The more is the level of this protein the rate of decline will be more and less will be the years to experience their memory and cognitive abilities deteriorate. The estimations of the protein can further help during treatment of the disease.

According to sources, their study included a survey on 60 individuals diagnosed with very mild AD. The diagnosis was made by investigating the rate of decline provided by VILIP-1 and VILIP-1/Aß-42. The CDR (Clinical Dementia rating) and baseline CSF measures of VILIP-1 and other biomarkers; tau, p-tau181, and Aß-42 were analyzed for an average of 2.6 years. Annual assessments included the CDR, CDR-sum of boxes (CDR-SB) and global composite scores.

The results concluded that the levels of baseline VILIP-1 and VILIP-1/Aß-42 in CSF were diagnosed higher in patients with very mild to mild AD. David M. Holtzman, MD, Professor and Chairman of the Department of Neurology at Washington University, who worked on the study, said: "The levels of VILIP-1 were generally better than other established biomarkers such as tau, p-tau, and amyloid beta 1-42 (Aß-42) in predicting rate of decline".

However, it is still to be proved that the protein, which is a neuronal calcium-sensor protein, acts as a stronger evidence to prove the signs of neuronal injury or of the ongoing injury to the brain cells. As it has been found that its prognostic ability is almost similar to that of tau.

The results provided have aroused the researchers' interest in the protein and are looking forward to carry out a much larger study to compare its worth with the other biomarkers.

Health: 
General: 
Region: